Capricor Therapeutics Inc (OTCMKTS:CAPR) was upgraded by Zacks Investment Research from a “sell” rating to a “hold” rating in a research note issued to investors on Tuesday.

According to Zacks, “Capricor Therapeutics, Inc. is a biotechnology company. It is focused on the development of novel therapeutics to prevent and treat heart disease. The Company has two drug candidates in development: Cenderitide and CU-NP. Capricor Therapeutics, Inc., formerly known as Nile Therapeutics, Inc., is based in San Mateo, California. “

Separately, HC Wainwright assumed coverage on Capricor Therapeutics in a report on Wednesday, July 6th. They set a “buy” rating and a $13.00 price target on the stock.

This story is the sole property of American Banking News and it was originally published by American Banking News. If you are reading this story on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. The original version of this article is available at

Capricor Therapeutics (OTCMKTS:CAPR) traded up 2.99% during trading on Tuesday, reaching $3.45. 46,475 shares of the company’s stock were exchanged. Capricor Therapeutics has a 52-week low of $1.88 and a 52-week high of $5.40. The company’s market capitalization is $61.94 million. The stock’s 50-day moving average price is $3.54 and its 200-day moving average price is $3.62.

Capricor Therapeutics (OTCMKTS:CAPR) last announced its quarterly earnings results on Monday, August 15th. The company reported ($0.26) EPS for the quarter, missing the consensus estimate of ($0.24) by $0.02. Equities analysts expect that Capricor Therapeutics will post ($1.04) earnings per share for the current year.

In related news, major shareholder Sinai Medical Center Cedars acquired 312,500 shares of the stock in a transaction dated Wednesday, September 21st. The shares were acquired at an average price of $3.20 per share, for a total transaction of $1,000,000.00. Following the completion of the purchase, the insider now owns 2,904,798 shares in the company, valued at approximately $9,295,353.60. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website.

An institutional investor recently raised its position in Capricor Therapeutics stock. Vanguard Group Inc. boosted its stake in Capricor Therapeutics Inc (OTCMKTS:CAPR) by 25.6% during the second quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 27,975 shares of the company’s stock after buying an additional 5,704 shares during the period. Vanguard Group Inc. owned 0.16% of Capricor Therapeutics worth $111,000 as of its most recent SEC filing.

Capricor Therapeutics Company Profile

Capricor Therapeutics, Inc is a clinical-stage biotechnology company focused on the discovery, development and commercialization of therapeutics. The Company focuses on discovering, developing and commercializing regenerative medicine and large molecule products for the treatment of disease, with a primary focus on the treatment of cardiovascular diseases, including orphan indications.

Get a free copy of the Zacks research report on Capricor Therapeutics (CAPR)

For more information about research offerings from Zacks Investment Research, visit

Receive News & Ratings for Capricor Therapeutics Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Capricor Therapeutics Inc and related companies with's FREE daily email newsletter.